Nicholas Hornstein, Assistant Professor at Northwell Health, shared Sawyer Bawek’s, Junior Chief Fellow at Cleveland Clinic, post on LinkedIn:
“Had the chance to give the colorectal cancer update at Best of ASCO Los Angeles.
Always fun to summarize a year of CRC data in ~20 minutes while pretending that is a normal thing to ask of a human being.
4 takeaways (without getting into some of the really exciting drugs that are coming to CRC soon):
- MSI-H CRC in complete clinical response on PD-1
Stopping at confirmed cCR looks safe. Maintenance may add toxicity without clear benefit. - BRAF V600E MSS mCRC
Encorafenib + cetuximab + chemotherapy is now a 1L standard. FOLFIRI is a great option, and FOLFOX is reasonable too. Either way, the targeted therapy backbone is here. - ctDNA / MRD
Not fully in NCCN yet, but increasingly actionable. I escalate select stage II patients, use it to frame de-escalation discussions, and strongly favor trials when possible. - Exercise
Prescribe it like we prescribe oxaliplatin.
30 min, 3x/week, ~80% max HR improves DFS/OS and is cost-saving.
CRC is moving fast. The challenge now is not just knowing the data, but figuring out how to apply it thoughtfully in clinic.
Grateful to be part of the conversation.”
Other articles featuring Nicholas Hornstein on OncoDaily.
